|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
GammaCan International, Inc. (GCAN.OB) Discovers Anti-Angiogenic Properties in Plasma-Derived IgG; Company Files Patent Application Pertaining to Disorders of Neovascularization Including Cancer and Other Diseases
6/28/2007 1:11:29 PM
KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced today that its Chief Scientist, Professor Yehuda Shoenfeld, M.D., FRCP, has discovered that gamma-immunoglobulins, or IgG, manufactured from human plasma, contain sub-fractions with potent anti-angiogenic properties which may have application in disorders of neovascularization, including cancer and other diseases. This discovery is the subject of a recent patent application filing with the U.S. Patent and Trademark Office.
|
|
|
|
|
|
|
|
|
|
|